MyAbilities Technologies, a company involved in smart health technology and workplace safety, has launched what is claimed to be the world's first online Digital Job Analysis database, JobXweb.com, it was reported yesterday.
The free database offers users access to more than 50,000 job titles, each with unique industry Digital Job Profiles including comprehensive analysis of the psychosocial, cognitive and physical demands in addition to a comprehensive job description. Each Digital Job Profile includes the essential demands of that job, whether they are physical, cognitive or psychosocial. Digital Job Profiles are shared with various stakeholders to support decisions leveraging the exact same set of data in a standardised, visual way to understand all the demands of the job.
Dr Michael Sonne, vice president, innovations and research at MyAbilities Technologies, said, 'Organisations can quickly search through a simple and free database to conduct a thorough review of the demands of thousands of jobs across all industries. We believe JobXweb.com is the first of its kind to offer easy access to a standardised analysis of thousands of jobs, and to present the information in a clear, shareable way.'
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Endo to share PFI and PFA data at American Orthopaedic Foot & Ankle Society Annual Meeting
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD